AU5512096A - Method of inhibiting restenosis using calreticulin - Google Patents

Method of inhibiting restenosis using calreticulin

Info

Publication number
AU5512096A
AU5512096A AU55120/96A AU5512096A AU5512096A AU 5512096 A AU5512096 A AU 5512096A AU 55120/96 A AU55120/96 A AU 55120/96A AU 5512096 A AU5512096 A AU 5512096A AU 5512096 A AU5512096 A AU 5512096A
Authority
AU
Australia
Prior art keywords
calreticulin
inhibiting restenosis
restenosis
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU55120/96A
Inventor
Alexandra Lucas
Marek Michalak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Alberta
Original Assignee
University of Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Alberta filed Critical University of Alberta
Publication of AU5512096A publication Critical patent/AU5512096A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU55120/96A 1995-05-17 1996-05-17 Method of inhibiting restenosis using calreticulin Abandoned AU5512096A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US44284495A 1995-05-17 1995-05-17
US442844 1995-05-17
US64941796A 1996-05-16 1996-05-16
US649417 1996-05-16
PCT/IB1996/000471 WO1996036643A1 (en) 1995-05-17 1996-05-17 Method of inhibiting restenosis using calreticulin

Publications (1)

Publication Number Publication Date
AU5512096A true AU5512096A (en) 1996-11-29

Family

ID=27033312

Family Applications (1)

Application Number Title Priority Date Filing Date
AU55120/96A Abandoned AU5512096A (en) 1995-05-17 1996-05-17 Method of inhibiting restenosis using calreticulin

Country Status (2)

Country Link
AU (1) AU5512096A (en)
WO (1) WO1996036643A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046283A1 (en) * 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6596690B2 (en) 1998-10-06 2003-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vasostatin as marrow protectant
US6867180B1 (en) 1998-10-06 2005-03-15 The United States Of America As Represented By The Department Of Health And Human Services Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth
AU6291799A (en) * 1998-10-06 2000-04-26 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
WO2001035986A2 (en) * 1999-11-16 2001-05-25 Hamilton Civic Hospitals Research Development Inc. Methods and compositions for modulating er-stress-induced cholesterol accumulation
JP5087201B2 (en) 2000-08-03 2012-12-05 ジョンズ・ホプキンス・ユニバーシティ Molecular vaccine with endoplasmic reticulum chaperone polypeptide linked to antigen
US6426220B1 (en) 2000-10-30 2002-07-30 Isis Pharmaceuticals, Inc. Antisense modulation of calreticulin expression
US9701725B2 (en) 2003-05-05 2017-07-11 The Johns Hopkins University Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
CA2594040A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
EP3046627B1 (en) * 2013-09-18 2019-10-23 The Board of Trustees of the Leland Stanford Junior University Modulation of efferocytosis pathways for treatment of atherosclerotic disease
US10822411B2 (en) 2014-09-15 2020-11-03 The Board Of Trustees Of The Leland Stanford Junior University Targeting aneurysm disease by modulating phagocytosis pathways

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5426097A (en) * 1993-04-06 1995-06-20 The Trustees Of Columbia University In The City Of New York Calreticulin: a novel antithrombotic agent

Also Published As

Publication number Publication date
WO1996036643A1 (en) 1996-11-21

Similar Documents

Publication Publication Date Title
PL327569A1 (en) Promedications of thrombosin inhibitors
AU7168696A (en) Inhibitors of regulatory pathways
AU5299696A (en) Methods of inhibiting cell-cell adhesion
PL321759A1 (en) Novel thrombosin inhibitors
AU1301697A (en) Tyrosin-derivate as alpha-v-integrin inhibitors
AU6174696A (en) Inhibitors of phospholipase a2
AU4756696A (en) Compounds for and method of inhibiting phosphodiesterase iv
AU6407696A (en) Method of identifying inhibitors of the jak-stat signal transduction pathway
AU5512096A (en) Method of inhibiting restenosis using calreticulin
PL323236A1 (en) Method of obtaining lerkanipidin chlorchydride
AU2277597A (en) New inhibitors of sh2-mediated processes
AU6109096A (en) Methods of inhibiting melanoma
GB9621852D0 (en) Inhibition of scale
PL327147A1 (en) Method of obtaining dihydropyrimidinones
AU6049796A (en) Lysyloxidase inhibitors
AU5311896A (en) Method of oxychlorination
AU5769996A (en) Method of marking an article
AU7506896A (en) Method for the simultaneous detection of polygenes
AU4916396A (en) Methods of inhibiting effects of il-6
AU7113996A (en) Methods of treating beta-amyloid-associated conditions
PL326978A1 (en) Method of obtaining dioxyaza bicyclohexanes
AU5825896A (en) Well inhibition
AUPN271195A0 (en) Method of selecting livestock
AU6860296A (en) Cycloanthelmintic inhibitors
AU7189096A (en) Method of transposing data